Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00684307
First received: May 22, 2008
Last updated: March 20, 2012
Last verified: March 2012
  Purpose

The main purpose of this study is to provide dose-guiding information by assessing the safety and tolerability of 4 different dosing regimens of an extended-release (ER) formulation of AZD0837 compared with well-controlled, dose-adjusted Vitamin-K antagonists (VKA) (aiming for an international normalized ratio (INR) 2.0 to 3.0) in patients with non-valvular atrial fibrillation (AF) with one or more additional risk factors for stroke.


Condition Intervention Phase
Nonvalvular Atrial Fibrillation
Drug: AZD0837
Drug: Vitamin-K antagonist at INR 2-3
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
Official Title: A Controlled, Randomized, Parallel, Multicentre Study to Assess Safety and Tolerability of the Oral Direct Thrombin Inhibitor AZD0837, Given as an Extended-release Formulation, in the Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Bleeding Events [ Time Frame: 36 weeks according to protocol. For patients who discontinued treatment the time frame was <36 weeks. Mean number of weeks was 21 weeks (baseline to end of treatment visit) ] [ Designated as safety issue: Yes ]
    Number of patients with a bleeding event while on study drug. Patients with multiple events are counted once

  • Creatinine [ Time Frame: 12 weeks according to protocol.(baseline to week 12 visit)  ] [ Designated as safety issue: Yes ]
    Change in Creatinine values from baseline to week 12 visit for patients while on study drug (week 12 visit-baseline)

  • Alanine Aminotransferase (ALAT) [ Time Frame: 36 weeks according to protocol. For patients who discontinued treatment the time frame was <36 weeks. Mean number of weeks was 21 weeks (baseline to end of treatment visit)  ] [ Designated as safety issue: Yes ]
    Number of patients while on study drug with ALAT>=3 times upper limit of normal.l

  • Bilirubin [ Time Frame: 36 weeks according to protocol. For patients who discontinued treatment the time frame was <36 weeks. Mean number of weeks was 21 weeks (baseline to end of treatment visit) ] [ Designated as safety issue: Yes ]
    Number of patients while on study drug with Bilirubin>=2 times upper limit of normal


Secondary Outcome Measures:
  • D-Dimer [ Time Frame: 14 weeks according to protocol.(enrolment to week 12 visit)  ] [ Designated as safety issue: Yes ]
    Change in D-Dimer values from enrolment to week 12 visit for VKA naïve patients while on study drug (week 12 visit-enrolment)

  • Activated Partial Thromboplastin Time (APTT) [ Time Frame: 12 weeks according to protocol.(baseline to week 12 visit)  ] [ Designated as safety issue: Yes ]
    Change in Activated partial thromboplastin time (APTT) from baseline to week 12 visit for VKA naïve patients while on study drug (week 12 visit-baseline)

  • Ecarin Clotting Time (ECT) [ Time Frame: 12 weeks according to protocol.(baseline to week 12 visit)  ] [ Designated as safety issue: Yes ]
    Change in Ecarin clotting time (ECT) from baseline to week 12 visit for patients while on study drug (week 12 visit-baseline)

  • Plasma Concentration of AZD0837 (Prodrug) [ Time Frame: 12 weeks after baseline according to protocol ] [ Designated as safety issue: No ]
    Assessment made on the week 12 visit

  • Plasma Concentration of AR-H067637XX (Active Metabolite) [ Time Frame: 12 weeks after baseline according to protocol ] [ Designated as safety issue: No ]
    Assessment made on the week 12 visit

  • Oral Clearance (CL/F) of AR-H067637XX (Active Metabolite) for C3435T Genotype TT [ Time Frame: 36 weeks according to protocol ] [ Designated as safety issue: No ]
    Oral clearance of AR-H067637XX in subgroup of patients with genotype TT for gene polymorphism ABCB1 C3435T

  • Oral Clearance (CL/F) of AR-H067637XX (Active Metabolite) for C3435T Genotype TC [ Time Frame: 36 weeks according to protocol ] [ Designated as safety issue: No ]
    Oral clearance of AR-H067637XX in subgroup of patients with genotype TC for gene polymorphism ABCB1 C3435T

  • Oral Clearance (CL/F) of AR-H067637XX (Active Metabolite) for C3435T Genotype CC [ Time Frame: 36 weeks according to protocol ] [ Designated as safety issue: No ]
    Oral clearance of AR-H067637XX in subgroup of patients with genotype CC for gene polymorphism ABCB1 C3435T


Enrollment: 1084
Study Start Date: February 2007
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
AZD0837 450 mg
Drug: AZD0837
ER tablet, PO, once daily for a period of 3-9 months.
Other Name: AZD0837
Experimental: 2
AZD0837 200 mg
Drug: AZD0837
ER tablet, PO, twice daily for a period of 3-9 months
Experimental: 3
AZD0837 300 mg
Drug: AZD0837
ER tablet, PO, once daily for a period of 3-9 months.
Other Name: AZD0837
Experimental: 4
AZD0837 150 mg
Drug: AZD0837
ER tablet, PO, once daily for a period of 3-9 months.
Other Name: AZD0837
Active Comparator: 5
Vitamin-K antagonist at INR 2-3
Drug: Vitamin-K antagonist at INR 2-3
Tablet, PO for a period of 3-9 months.
Other Name: Warfarin

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Nonvalvular AF (NVAF) verified by at least two ECGs in the last year separated by at least one week.
  • Previous cerebral ischemic attack (stroke or TIA, >30 days prior to randomization)
  • Previous systemic embolism.
  • Symptomatic congestive heart failure (CHF)
  • Impaired left ventricular systolic function
  • Diabetes mellitus
  • Hypertension requiring anti-hypertensive treatment.

Exclusion Criteria:

  • AF secondary to reversible disorders, eg hyperthyroidism, drugs and pulmonary embolism
  • Known contraindication to VKA treatment
  • Presence of a valvular heart disease, mechanical heart valves, active endocarditis, left ventricular aneurysm or thrombus, atrial myxoma or any condition other than AF requiring chronic anticoagulation treatment
  • Conditions associated with increased risk of major bleeding for example: history of intracranial bleeding, history of bleeding gastrointestinal disorder or major surgical procedure or trauma two weeks prior to randomization
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00684307

Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Gregory Y Lip, Prof University Department of Medicine, City Hospital, Birmingham, B18 7QH, England, UK
  More Information

No publications provided by AstraZeneca

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00684307     History of Changes
Other Study ID Numbers: D1250C00008
Study First Received: May 22, 2008
Results First Received: August 17, 2011
Last Updated: March 20, 2012
Health Authority: Austria: Agency for Health and Food Safety
Denmark: Danish Medicines Agency
Hungary: National Institute of Pharmacy
Ireland: Irish Medicines Board
Norway: Norwegian Medicines Agency
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Russia: Ministry of Health of the Russian Federation
Sweden: Medical Products Agency
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by AstraZeneca:
Anticoagulant Treatment
Risk Factors For Stroke

Additional relevant MeSH terms:
Atrial Fibrillation
Stroke
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Antithrombins
Vitamin K
Vitamins
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anticoagulants
Hematologic Agents
Therapeutic Uses
Micronutrients
Growth Substances
Physiological Effects of Drugs
Antifibrinolytic Agents
Fibrin Modulating Agents
Hemostatics
Coagulants

ClinicalTrials.gov processed this record on July 28, 2014